Healthcare • NYSE
According to Zyberno, CONMED CORPORATION (CNMD) shows a Value Trap signal — WEAK BUSINESS (36/100) with an apparent Margin of Safety of +68.0%, but a Brina Gap of -12.2% reveals the current price still assumes faster growth than the business can deliver.
According to Zyberno's DCF model, CONMED CORPORATION (CNMD) trades at $49.98 against an estimated intrinsic value per share of $156.14 — a +68.0% Margin of Safety based on Owner Earnings of $150.88M TTM, projected at 28.1% growth for 10 years with a 2.5% terminal growth rate. The Brina Gap of -12.2% weakens the case: based on the company's ROIC (4.6%) and reinvestment rate (-17.0%), the business can fundamentally grow at -0.8% — but the current enterprise value implies the market expects 11.4%. This places CNMD in the Value Trap quadrant of the Brina Matrix — a value-trap signal where the apparent discount is undermined by overpriced growth expectations. Zyberno's model translates this into a 5-year expected return of 50.7% annually.
Over the trailing twelve months, CNMD generated $150.88M in Owner Earnings. Capital was deployed as follows: $24.75M paid as dividends, $19.81M invested in capital expenditures. Reinvestment rate: -17.0%. Owner Earnings have grown at 28.1% annually over the trailing five years using log-linear regression.